Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Wedbush Initiates Coverage On Aclaris Therapeutics with Outperform Rating, Announces Price Target of $8

Author: Benzinga Newsdesk | May 28, 2025 07:30am

Wedbush analyst Martin Fan initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform rating and announces Price Target of $8.

Posted In: ACRS